Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2003 Oct;95(10):977–981.

Cardiotoxicities of paclitaxel in African Americans.

Padma Kamineni 1, Kalpana Prakasa 1, Syed P Hasan 1, Ravi Akula 1, Fitzroy Dawkins 1
PMCID: PMC2594483  PMID: 14620711

Abstract

PURPOSE: To assess the cardiac disturbances in African-American patients treated with paclitaxel. PATIENTS AND METHODS: One-hundred-nineteen African-American patients received paclitaxel for various cancers at Howard University Hospital during the years 1993-2001. Medical records of 100 patients were available for review. Sixty-seven percent were women and 33% were men. Ages ranged between 26-85 years (mean age 51 years). Medical records were reviewed for demographics, types of cancer, dosage and frequency of paclitaxel and other chemotherapeutic agents, events during paclitaxel infusion, initial and subsequent EKGs, and hospital admissions. We used the Chi-square test to compare EKG changes in patients with and without cardiac risk factors. RESULTS: Ninety patients received paclitaxel as second-line chemotherapy, and 10 patients were treated with paclitaxel as a single agent. Dosage of paclitaxel ranged from 75-200 mg/square meter and was administered every 1-3 weeks. The electrocardiogram readings revealed the following cardiac events: 26% sinus tachycardia, 13% non-specific T-wave changes, 6% myocardial infarction, 4% prolonged QT interval, 4% left-bundle branch block, 3% right-bundle branch block, 3% sinus bradycardia, 2% premature atrial contractions, 2% premature ventricular contractions, 2% atrial flutter, and 1% atrial fibrillation. Eighty percent of the patients had risk factors for coronary artery disease. These cardiac disturbances were observed from day one to a maximum of eight years after receiving the chemotherapy and were independent of dosage of paclitaxel. Sixty percent of our study population had underlying co-morbid conditions, such as dehydration, anemia, sepsis, and hypoxia. The EKG changes observed in patients with underlying cardiac risk factors were statistically significant (p<0.0001). CONCLUSION: Paclitaxel was not associated with significant symptomatic cardiac disturbances during infusion in our study population. Caution should be exercised in patients with underlying cardiac disease and risk factors for coronary artery disease. However more prospective studies with closer follow-up during paclitaxel infusion are needed to assess its cardiotoxicities.

Full text

PDF
977

Images in this article

978Figure 1
on p.978
979Figure 2
on p.979

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Billingham M. E., Bristow M. R., Glatstein E., Mason J. W., Masek M. A., Daniels J. R. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol. 1977 Mar;1(1):17–23. [PubMed] [Google Scholar]
  2. Buja L. M., Ferrans V. J., Mayer R. J., Roberts W. C., Henderson E. S. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer. 1973 Oct;32(4):771–788. doi: 10.1002/1097-0142(197310)32:4<771::aid-cncr2820320407>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  3. Chang A. Y., Kim K., Glick J., Anderson T., Karp D., Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst. 1993 Mar 3;85(5):388–394. doi: 10.1093/jnci/85.5.388. [DOI] [PubMed] [Google Scholar]
  4. Cherifi S., Hermans P., De Wit S., Cantinieaux B., Clumeck N. Acute pulmonary hypertension following paclitaxel in a patient with AIDS-related primary effusion lymphoma. Clin Microbiol Infect. 2001 May;7(5):277–278. doi: 10.1046/j.1469-0691.2001.00243.x. [DOI] [PubMed] [Google Scholar]
  5. Davis Sharon K., Liu Yong, Gibbons Gary H. Disparities in trends of hospitalization for potentially preventable chronic conditions among African Americans during the 1990s: implications and benchmarks. Am J Public Health. 2003 Mar;93(3):447–455. doi: 10.2105/ajph.93.3.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Drisko Jeanne A., Chapman Julia, Hunter Verda J. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr. 2003 Apr;22(2):118–123. doi: 10.1080/07315724.2003.10719284. [DOI] [PubMed] [Google Scholar]
  7. Honda Y., Grube E., de La Fuente L. M., Yock P. G., Stertzer S. H., Fitzgerald P. J. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation. 2001 Jul 24;104(4):380–383. doi: 10.1161/hc2901.094149. [DOI] [PubMed] [Google Scholar]
  8. Jekunen A., Heikkilä P., Maiche A., Pyrhönen S. Paclitaxel-induced myocardial damage detected by electron microscopy. Lancet. 1994 Mar 19;343(8899):727–728. doi: 10.1016/s0140-6736(94)91603-9. [DOI] [PubMed] [Google Scholar]
  9. Laher S., Karp S. J. Acute myocardial infarction following paclitaxel administration for ovarian carcinoma. Clin Oncol (R Coll Radiol) 1997;9(2):124–126. doi: 10.1016/s0936-6555(05)80452-2. [DOI] [PubMed] [Google Scholar]
  10. Mackay B., Ewer M. S., Carrasco C. H., Benjamin R. S. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):203–211. doi: 10.3109/01913129409016291. [DOI] [PubMed] [Google Scholar]
  11. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
  12. Minotti G., Saponiero A., Licata S., Menna P., Calafiore A. M., Teodori G., Gianni L. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res. 2001 Jun;7(6):1511–1515. [PubMed] [Google Scholar]
  13. Rowinsky E. K., Eisenhauer E. A., Chaudhry V., Arbuck S. G., Donehower R. C. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993 Aug;20(4 Suppl 3):1–15. [PubMed] [Google Scholar]
  14. Rowinsky E. K., McGuire W. P., Guarnieri T., Fisherman J. S., Christian M. C., Donehower R. C. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991 Sep;9(9):1704–1712. doi: 10.1200/JCO.1991.9.9.1704. [DOI] [PubMed] [Google Scholar]
  15. Shek T. W., Luk I. S., Ma L., Cheung K. L. Paclitaxel-induced cardiotoxicity. An ultrastructural study. Arch Pathol Lab Med. 1996 Jan;120(1):89–91. [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES